InsiderTradesSIGMA

PicksTOP Companies Executives Performance Blog Topics

InsidersTradesSigma

InsiderTradesSIGMA

Multi-market insider intelligence. Official public filings, re-aggregated and scored. Private beta.

FRUSDEGBCHCAITESNLBENOSEFIDKAUATIEBRINJP+ 8 markets

Recommendations
Companies
Insiders
Performance
Backtest
Compare

Methodology
How it works
Glossary
API docs
Status
Blog

Sign in
Create account
Portfolio
API keys
Alerts
Upgrade

Privacy
Terms
Cookies
Contact
About

Built in Paris. Public sources across 28 markets: AMF France, SEC EDGAR Form 4 US, BaFin Germany, SIX SER Switzerland, RNS United Kingdom, SEDI Canada, Consob Italy, CNMV Spain, AFM Netherlands, FSMA Belgium, Oslo Bors Norway, Nasdaq Helsinki, Nasdaq Copenhagen, ASX Australia, FMA Austria, CVM Brazil, HKEX Hong Kong, BSE-Sofia Bulgaria, Tadawul Saudi Arabia, DART South Korea, EDINET Japan, SSE and SZSE China, SEBI India, KNF Poland, PSE Philippines, NZX New Zealand, JSE South Africa. Prices + fundamentals via Yahoo Finance, STOXX 600 sector ETFs (iShares Xetra). Stack: Next.js 16, Prisma, Vercel. Live out-of-sample tracker since 2026-05-16. Methodology audits: /methodologie and /docs/method-review/.

Sources: official public filings under MAR Art.19 (EU and EEA), SEC Section 16 / Form 4 (US), Art.56 SESTA (CH, SIX SER), NI 55-104 / SEDI (CA), Corporations Act s205G (AU) and equivalent regimes. Signals on this site are for educational use only and do not constitute investment advice within the meaning of MiFID II / SEC Reg-IA. Past performance does not guarantee future results. Swiss SIX SER filings are anonymised by law (role only, no name).

Theme: dark (range regime detected on CAC40 90d · as of 2026-05-25)

© 2026 Insiders TradesΣ·Private beta·Hosted on Vercel

All systems operational

InsidersTradesSigma

Jeshika Hiten Parikh | Insider Transactions

← Executives ★ Sign in to follow

JH

Jeshika Hiten Parikh

ININ·SEBI (PIT + SAST)

Senores Pharmaceuticals Limited

Cumul. flow

0

Total declarations

0

Company

—

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

Explore the complete record of transactions filed by Jeshika Hiten Parikh. Director active across 1 companies, notably Senores Pharmaceuticals Limited. In total, 16 disclosures have been published. The latest transaction was filed on 12 February 2025 (Purchase). Regulator: SEBI (PIT + SAST). The full history is openly available.

Declarations16 total

Executives●PurchaseSSenores Pharmaceuticals Limited0SEBI

J

Jeshika Hiten Parikh

€729124 shares@ €5.8772

Equity Shares

SEBI:ffc4a4f58d558a1ae52789eb551b2cff28f45d1d·12 Feb 2025

Ideal exit: 9 Nov 2025 (T+270)

Executives●PurchaseSSenores Pharmaceuticals Limited0SEBI

J

Jeshika Hiten Parikh

€9416 shares@ €5.8605

Equity Shares

SEBI:525158a987f3cad1d276b249e5e67bf207c92730·12 Feb 2025

Ideal exit: 9 Nov 2025 (T+270)

Executives●PurchaseSSenores Pharmaceuticals Limited0SEBI

J

Jeshika Hiten Parikh

€9416 shares@ €5.8584

Equity Shares

SEBI:ee7bff4e0aab073abfee54c0bc290d1e31404a9d·12 Feb 2025

Ideal exit: 9 Nov 2025 (T+270)

Executives●PurchaseSSenores Pharmaceuticals Limited0SEBI

J

Jeshika Hiten Parikh

€10518 shares@ €5.8587

Equity Shares

SEBI:8b6a93e9e369ba5a8427a1df82b502d4d7af2abb·12 Feb 2025

Ideal exit: 9 Nov 2025 (T+270)

Executives●PurchaseSSenores Pharmaceuticals Limited0SEBI

J

Jeshika Hiten Parikh

€48282 shares@ €5.8772

Equity Shares

SEBI:1bf15e37441c6c72ad27fe6311cde81cce51720b·12 Feb 2025

Ideal exit: 9 Nov 2025 (T+270)

Executives●PurchaseSSenores Pharmaceuticals Limited0SEBI

J

Jeshika Hiten Parikh

€35861 shares@ €5.8743

Equity Shares

SEBI:d17222002197a032535acb22e7da2677927cfacd·12 Feb 2025

Ideal exit: 9 Nov 2025 (T+270)

Executives●PurchaseSSenores Pharmaceuticals Limited0SEBI

J

Jeshika Hiten Parikh

€15927 shares@ €5.8747

Equity Shares

SEBI:4794725fe4d511069dd8ce2dc4e97d2be73f84f3·12 Feb 2025

Ideal exit: 9 Nov 2025 (T+270)

Executives●PurchaseSSenores Pharmaceuticals Limited0SEBI

J

Jeshika Hiten Parikh

€234 shares@ €5.8744

Equity Shares

SEBI:a56444627ea0bee00bd3f7cf51367a732ddee6e4·12 Feb 2025

Ideal exit: 9 Nov 2025 (T+270)

Executives●PurchaseSSenores Pharmaceuticals Limited0SEBI

J

Jeshika Hiten Parikh

€37063 shares@ €5.876

Equity Shares

SEBI:092b33931d783309750357eed1b712b3c42ee8dc·12 Feb 2025

Ideal exit: 9 Nov 2025 (T+270)

Executives●PurchaseSSenores Pharmaceuticals Limited0SEBI

J

Jeshika Hiten Parikh

€1,698289 shares@ €5.8766

Equity Shares

SEBI:268247cacb43e7a92440dbd9d4cf896e5a2a45ec·12 Feb 2025

Ideal exit: 9 Nov 2025 (T+270)

Executives●PurchaseSSenores Pharmaceuticals Limited0SEBI

J

Jeshika Hiten Parikh

€5,419922 shares@ €5.8772

Equity Shares

SEBI:bff1cfa353bff44dc336ae46b3c4d283fa30de4c·12 Feb 2025

Ideal exit: 9 Nov 2025 (T+270)

Executives●PurchaseSSenores Pharmaceuticals Limited0SEBI

J

Jeshika Hiten Parikh

€61 shares@ €5.8661

Equity Shares

SEBI:783cb93172f1e382a25b714a0d11908311c411b2·12 Feb 2025

Ideal exit: 9 Nov 2025 (T+270)

Executives●PurchaseSSenores Pharmaceuticals Limited0SEBI

J

Jeshika Hiten Parikh

€234 shares@ €5.8577

Equity Shares

SEBI:8124b9a76c5316d25bb81ab68faf00d9a92aa539·12 Feb 2025

Ideal exit: 9 Nov 2025 (T+270)

Executives●PurchaseSSenores Pharmaceuticals Limited0SEBI

J

Jeshika Hiten Parikh

€1,582270 shares@ €5.8605

Equity Shares

SEBI:44b96a289696edcdb050d6d83bc3636e6ed401bf·12 Feb 2025

Ideal exit: 9 Nov 2025 (T+270)

Executives●PurchaseSSenores Pharmaceuticals Limited0SEBI

J

Jeshika Hiten Parikh

€17630 shares@ €5.8598

Equity Shares

SEBI:b31e3fc5b543cd5bb3d8c49fe1c225e7be29dae5·12 Feb 2025

Ideal exit: 9 Nov 2025 (T+270)

Executives●PurchaseSSenores Pharmaceuticals Limited0SEBI

J

Jeshika Hiten Parikh

€42873 shares@ €5.8594

Equity Shares

SEBI:1816a5b0a89f9f28f885b38dcc210a3644a3b30d·12 Feb 2025

Ideal exit: 9 Nov 2025 (T+270)

16 of 16 declarations